This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
2024
- Our company has been selected among the top 5% in corporate governance evaluations for three consecutive terms.
- The oral solution of the “MS-20″ has been granted invention patents in Japan, Australia, and South Korea.
- The oral solution of “HERBIRON” has been granted an invention patent in Thailand.
- Safety evaluation data of the fermented soybean extract has publicated in the renowned international journal Food Science & Nutrition.
2023
- Our company has again been selected among the top 5% in corporate governance evaluations.
- Awarded the Silver Award in the Sustainability Report Category of the TCSA “Taiwan Corporate Sustainability Awards”.
- The “Traditional Chinese Medicine Symbiotic Fermentation Technology Platform” received the National Innovation Excellence Award.
2022
- Our company was selected among the top 5% in corporate governance evaluations.
- The oral solution of the “MS-20″ was granted invention patents in the United States, Brazil, and the Republic of China.
- The oral solution of “HERBIRON” was granted an invention patent in Malaysia.
- Our Board of Directors has approved the establishment of a Sustainability Development Committee to further our ESG and long-term growth commitments.
- Subsidiary Microbio (Shanghai) Co., Ltd. and Oneness Biotech signed an agreement on the development of nucleic acid drugs involving “lipid-based targeted delivery technology”.
- Subsidiary Microbio (Shanghai) Co., Ltd. and Oneness Biotech jointly developed the broad-spectrum nucleic acid therapeutic drug SNS812 for COVID-19; it received FDA approval to enter Phase I clinical trials.
- Subsidiary Microbio (Shanghai) Co., Ltd. completed an international CRO-commissioned study on the efficacy of FB825 in treating moderate-to-severe atopic dermatitis.
- Joint publication with Microbio (Shanghai) Co., Ltd. and Oneness Biotech of the antiviral nucleic acid drug SNS812’s preclinical results in a peer-reviewed SCI journal (EMBO Molecular Medicine), with formal external publication.
2021
- The oral solution of the “MS-20″ has been granted invention patents in the United States and Singapore.
- Subsidiary Microbio (Shanghai) Co., Ltd. received an official notification from China’s Center for Drug Evaluation (CDE) under the National Medical Products Administration, and formally submitted a New Drug Application (NDA) for ON101 topical diabetic foot ulcer drug.
- Established a “Next-Generation Targeting” technology platform.
2020
- Subsidiary Microbio (Shanghai) Co., Ltd. and its affiliates, together with Oneness Biotech Co., Ltd., signed a co-development and licensing agreement with global pharmaceutical company LEO PHARMA A/S for the novel monoclonal antibody drug FB825.
- Subsidiary Microbio (Shanghai) Co., Ltd. received approval from Taiwan’s Ministry of Health and Welfare to conduct a Phase II clinical trial of FB825 for the treatment of moderate-to-severe adult atopic dermatitis.
- Microbio was included in the MSCI Global Small Cap Index.
- The oral solution of “HERBIRON” was granted invention patents in the Republic of China, Indonesia, and South Korea.
- The oral solution of the “MS-20″ obtained a Canadian pharmaceutical patent.
2019
- The oral solution of ” HERBIRON ” was granted a patent in Singapore.
- The new anti-Hepatitis C drug MB-110 has been granted invention patents in Europe and China.
- The oral solution of the “MS-20″ received patents in Iraq, the United Arab Emirates, India, and Malaysia.
- The new drug MS-20 and HERBIRON received marketing approval in mainland China for Microbio (Shanghai) Co., Ltd. subsidiary.
- Compound MB-6 received a patent in the Republic of China.
- Established a “Hydrofluoroalkyl Functionalized Natural Product Fermentation” technology platform.
2018
- MS-20 (Chemo young) obtained invention patents in Taiwan, the United States, Japan, Hong Kong, South Korea, Europe and Indonesia
2016
- Joint development of the Pingtung County Nanjhou Township with ONENESS to establish PIC/S GMP Pharmaceutical Factory and Sightseeing Pharmaceutical Factory Park
2015
-
Herbiron wins Biomedical Quality Award
-
MB-110 (anti-C hepatitis new drug) passed the US FDA phase I human clinical trial application
2013
-
Herbiron obtained the first compound herbs new drug certificate
-
MB-6 conducts Phase III human clinical trials
2011
- MS-20 (Chemo young) obtained the first certificate of oral solution for cancer new drug.
2008
-
MB-6 obtained the US FDA Phase II Human Clinical Trial approval
-
Became the first “Biotech New Drug Company” in Taiwan
-
Herbiron conducts Phase III human clinical trials
2006
- Microbio’s stock has been officially listed on over the counter market (4128)
2004
-
Established Microbio (Shanghai) Co., Ltd.
-
Established Taiwan’s first “New Drug Research and Development Center”
2001
-
Longtan Plant was established and passed the GMP certification
-
MS-20 (Chemo young) conducts the phase III of human clinical trials
2000
-
Established Microbio Co., Ltd.
1997
- Establishment of the gut microbiota symbiotic fermentation technology